FDA Follow-On Biologics Process Could Allow Use Of Surrogates
This article was originally published in The Pink Sheet Daily
Executive Summary
Follow-on versions of erythropoietin might be able to use an increase in red blood cells as a surrogate endpoint under the upcoming FDA guidance, the agency's Anthony Mire-Sluis says. The guidance will cover general requirements, as well as product-specific issues for generic biologics submissions.